Вы искали: acarbose (Английский - Мальтийский)

acarbose
acarbose

acarbose is contraindicated in patients with intestinal obstruction.
acarbose huwa kontraidnikat f’pazjenti b’ostruzzjoni intestinali.

trials investigating the combination with other insulin secretagogues and acarbose have not been
ma sarux studji kliniċi li jinvestigaw t- teħid tal- prodott flimkien ma 'prodotti oħra li jikkawżaw s- sekrezzjoni ta ’ l- insulina u ma ’ acarbose.

19 trials investigating the combination with other insulin secretagogues and acarbose have not been performed.
ma sarux studji kliniċi li jinvestigaw t- teħid tal- prodott flimkien ma 'prodotti oħra li jikkawżaw s- sekrezzjoni ta ’ l- insulina u ma ’ acarbose.

in the absence of pharmacokinetic interaction studies, alli is not recommended to be used by patients receiving acarbose.
fin-nuqqas ta’ studji farmakokinetiċi dwar l-interazzjoni, alli mhux irrakkomandat biex jintuża minn pazjenti li jkunu qed jieħdu acarbose.

acarbose in the absence of pharmacokinetic interaction studies, the concomitant administration of orlistat with acarbose should be avoided.
3 fin- nuqqas ta ’ studji farmakokinetiċi dwar l- interazzjonijiet, l- għoti ta ’ orlistat flimkien ma ’ acarbose għandu jiġi evitat.

concomitant administration of rosiglitazone with the oral antihyperglycaemic agents glibenclamide and acarbose did not result in any clinically relevant pharmacokinetic interactions.
meta rozoglitazone ġie mogħti flimkien ma’ l-aġenti anti-ipergliċemiċi orali glibenclamide u acarbose ma’ rriżultax li kien hemm xi interazzjonijiet farmakokinetiċi klinikament relevanti.

concomitant administration with the oral anti-diabetic agents metformin, glibenclamide and acarbose did not result in any clinically relevant pharmacokinetic interactions with rosiglitazone.
meta rosiglitazone ġie mogħti flimkien ma’ l-aġenti anti-diabetiċi orali metformin, glibenclamide u acarbose ma’ rriżultax li kien hemm xi interazzjonijiet farmakokinetiċi klinikament relevanti.

xenical is not recommended for people taking acarbose (an anti-diabetic drug used to treat type 2 diabetes mellitus).
xenical mhux rakkomandat għall-persuni li jieħdu acarbose (mediċina kontra d-dijabete wżata biex tikkura dijabete mellitus tat-tip 2).

concomitant administration of rosiglitazone with the oral anti-diabetic agents metformin, glimepiride, glibenclamide and acarbose did not result in any clinically relevant pharmacokinetic interactions.
it-teħid flimkien ta’ rosiglitazone ma’ l-aġenti anti-dijabetiċi mill-ħalq metformin, glimepiride, glibenclamide u acarbose ma rriżultaw f’ebda interazzjoni farmakokinetika rilevanti klinika.

acarbose, (an anti-diabetic drug used to treat type 2 diabetes mellitus). alli is not recommended for people taking acarbose.
acarbose (mediċina kontra d-dijabete wżata biex tikkura dijabete mellitus tat-tip 2). alli mhux irrakkomandat għall-persuni li jkunu qed jieħdu acarbose.

talk to your doctor or pharmacist before taking alli if you are taking • amiodarone, used for heart rhythm problems. • acarbose, used for diabetes.
kellem lit- tabib jew lill- ispiżjar tiegħek qabel tieħu alli jekk qed tieħu • amiodarone, użat għall- problemi fir- ritmu tal- qalb • acarbose, użat għad- dijabete

thyroid hormone replacement therapy, oral hypoglycaemics, (e.g. metformin, acarbose, sulphonylurea agents, pioglitazone, empagliflozin, dpp-4-inhibitors like sitagliptin or saxagliptine, ),
terapija biex tpatti għan-nuqqas tal-ormoni tat-tirojde, mediċini ipogliċemiċi orali, (eż. metformin, acarbose, sustanzi sulphonylurea, pioglitazone, empagliflozin, impedituri ta’ dpp-4 bħal sitagliptin jew saxagliptine),